Good stuff Joe. I know she is limited to what she can say, but her first response about the meeting being “regarding avenues to advance in a registrational trial” makes it sound like going to phase III. But maybe it will be the required confirmatory trial for accelerated approval. Again, I think it looks good. Put together the PFS with OS and the biomarkers showing the effects and the negligible toxicity. FDA targeting drugs in high unmet needs. I guess we have to wait and see. I am concerned maybe something got leaked that they didn’t get AA and are moving forward with a standard PHIII is what is tanking our investment. Butt I wait…
IMM Price at posting:
24.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)